01Nov 2023
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma

This retrospective study aimed to assess the efficacy of high-dose methotrexate (HD-MTX) in preventing CNS progression in high-risk aggressive B-cell lymphoma patients. Including 2,418 patients, those treated with HD-MTX showed a lower risk of CNS progression, but significance was lost in those in complete response. Subgroup analyses lacked power for definitive conclusions. HD-MTX use did not significantly reduce the risk of CNS progression, indicating limited efficacy in this large study.

  • #oncology

Like

Save

Share